Reboxetine induced erectile dysfunction and spontaneous ejaculation during defecation and micturition

Area of Science:

• Pharmacology
• Neuroscience
• Psychiatry

Background:

• Depression treatment often involves selective serotonin reuptake inhibitors (SSRIs) or norepinephrine reuptake inhibitors (NRIs).
• Venlafaxine XR, a serotonin-norepinephrine reuptake inhibitor (SNRI), was initially prescribed for a patient with depression.
• The patient experienced delayed and absent ejaculation with venlafaxine XR, prompting a switch to reboxetine.

Observation:

• Reboxetine, a selective norepinephrine reuptake inhibitor (SNRI), was initiated for depression management.
• Within two weeks, the patient developed erectile dysfunction and premature ejaculation.
• By the eighth week, the patient reported seminal emission and ejaculation during defecation and micturition.

Findings:

• Reboxetine induced significant sexual dysfunction, including erectile dysfunction, premature ejaculation, and spontaneous ejaculations during non-sexual activities.
• These adverse sexual effects were fully reversible upon discontinuation of reboxetine and initiation of sertraline, a selective serotonin reuptake inhibitor (SSRI).

Implications:

• This case highlights that reboxetine, despite being reported to have a lower incidence of sexual side effects, can induce severe sexual dysfunction in susceptible individuals.
• Thorough sexual dysfunction assessment is crucial during antidepressant therapy, especially when switching medications.
• Individual patient vulnerability to psychotropic medication side effects warrants consideration in clinical practice.